# Molecular insights into NLRP3 inflammasome and miRNA modulation in oral cancer

**Authors:** Deborah Mannino, Morena D’Ariano, Ivana Bello, Irene Paterniti, Giovanna Casili, Elisabetta Panza

PMC · DOI: 10.3389/fphar.2025.1713259 · Frontiers in Pharmacology · 2026-01-05

## TL;DR

This paper reviews how the NLRP3 inflammasome and microRNAs influence oral cancer development and progression.

## Contribution

The paper highlights the dual role of NLRP3 and the therapeutic potential of targeting the NLRP3-miRNA axis in oral cancer.

## Key findings

- Elevated NLRP3 expression correlates with tumor progression and poor survival in oral squamous cell carcinoma.
- MicroRNAs like miR-22-3p suppress NLRP3 activity, inhibiting cancer cell proliferation and invasion.
- Targeting NLRP3 or its regulatory miRNAs may offer therapeutic benefits in oral cancer.

## Abstract

The NLRP3 inflammasome, a cytosolic multiprotein complex composed of NLRP3, ASC, and caspase-1, orchestrates the maturation of interleukin-1β (IL-1β) and interleukin-18 (IL-18) and the induction of pyroptosis, acting as a central mediator of innate immunity. Although physiologically protective, aberrant NLRP3 activation has been increasingly implicated in tumorigenesis. In oral squamous cell carcinoma (OSCC), current evidence points to a predominantly pro-tumorigenic role, with elevated NLRP3 expression correlating with tumor progression, lymph node metastasis, advanced pathological stage, and reduced survival. Functional studies demonstrate that genetic silencing or pharmacological inhibition of NLRP3 enhances apoptosis and reduces tumor burden. An additional regulatory layer is provided by microRNAs (miRNAs), which fine-tune NLRP3 expression at the post-transcriptional level. Since the identification of miR-223-3p as the first miRNA to directly target NLRP3, several miRNAs, including miR-22-3p, miR-7-5p, and miR-30e-5p, have been shown to suppress NLRP3 activity in various pathological settings, including oral squamous cell carcinoma, where miR-22-3p downregulates NLRP3, inhibiting its proliferation, migration, and invasion. Therefore, the NLRP3 inflammasome represents a key player in cancer development, and its regulation by miRNAs highlights its importance and clinical potential. This review summarizes mechanistic and clinical knowledge on the biology of NLRP3, highlights its dual role in cancer hallmarks, and discusses the therapeutic promise of targeting the NLRP3-miRNA axis in the management of oral cancer.

## Linked entities

- **Genes:** NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548], STS (steroid sulfatase) [NCBI Gene 412], Caspase1 (caspase-1) [NCBI Gene 692604], IL1B (interleukin 1 beta) [NCBI Gene 3553], IL18 (interleukin 18) [NCBI Gene 3606], mir-7 (mir-7 stem loop) [NCBI Gene 12798133]
- **Diseases:** oral squamous cell carcinoma (MONDO:0004958)

## Full-text entities

- **Genes:** IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, MIR7-3 (microRNA 7-3) [NCBI Gene 407045] {aka MIRN7-3, hsa-mir-7-3, mir-7-3}, PYCARD (PYD and CARD domain containing) [NCBI Gene 29108] {aka ASC, CARD5, TMS, TMS-1, TMS1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, MIR223 (microRNA 223) [NCBI Gene 407008] {aka MIRN223, miRNA223, mir-223}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}
- **Diseases:** cancer (MESH:D009369), tumorigenic (MESH:D002471), OSCC (MESH:D000077195), lymph node metastasis (MESH:D008207), tumorigenesis (MESH:D063646), oral cancer (MESH:D009062)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12812990/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12812990/full.md

## References

107 references — full list in the complete paper: https://tomesphere.com/paper/PMC12812990/full.md

---
Source: https://tomesphere.com/paper/PMC12812990